Elanco Animal Health Incorporated Common Stock (ELAN) — 分析摘要
Elanco Animal Health Incorporated Common Stock（ELAN）的市值为13.17十亿美元，最近一年的营收同比增长了+6.2%。净利润率为-4.9%。当前市盈率为-54.4倍。
核心要点
- 营收同比变化+6.2%
- 净利润率-4.9%
- 市盈率-54.4倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，ELAN的营收增长为+6.2%，市盈率为-54.4倍。
Elanco Animal Health Incorporated Common Stock (ELAN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 0.0x — 盈利不足以覆盖利息支出
Debt/EBITDA 为 5.6x — 杠杆偏高
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
9,900
总部
INDIANAPOLIS, IN
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。